Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated.

Elodie Gautier-VeyretAnne Thiebaut-BertrandMatthieu RoustitLéa BolcatoJulie DepeissesMathilde SchachererGabriel SchummerXavier FonroseFrançoise Stanke-Labesque

Published in: British journal of clinical pharmacology (2020)

The combined genetic score did not predict low VRC exposure in patients with inflammation, which is frequent in patients with invasive fungal infections. Strategies for the individualization of VRC dose should integrate the inflammatory status of patients in addition to pharmacogenetic variants.

Keyphrases

oxidative stress
end stage renal disease
newly diagnosed
ejection fraction
copy number
chronic kidney disease
prognostic factors
peritoneal dialysis
genome wide
emergency department
gene expression
replacement therapy
smoking cessation
electronic health record